With the development of drugs for type 2 diabetes mellitus (T2DM), many new hypoglycemic drugs have been widely used in clinic, such as dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i). These drugs have significant hypoglycemic effect, low risk of hypoglycemia, with cardio- and renal-protective effect.
For instance, the incretin effect, which is the amplification of insulin secretion when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body tolerate carbohydrate/glucose ingestion. Incretin peptides regulate islet hormone secretion, gut motility, appetite and body weight, and immune function, providing a scientific basis for utilizing incretin-based therapies in the treatment of type 2 diabetes. SGLT-2 inhibitors could also hypothetically lower albuminuria by restoring the charge and/or size selectivity of the glomerular basement membrane. Alternatively, improvement in tubular reabsorption of filtered albumin can potentially decrease albuminuria. 6 SGLT-2 inhibition reduces the reabsorption of filtered sodium and glucose in the proximal tubule, and thereby reduces the oxygen-consuming transport workload.
These novel hypoglycemic drugs bring benefits to patients with diabetes more than hypoglycemic effect. It is necessary to evaluate the safety of these new hypoglycemic drugs. Meanwhile, it is also hoped that more research should provide evidence and recommendations for effective and safe clinical use of these new hypoglycemic drugs.
This Research Topic aims to evaluate the safety of hypoglycemic drugs, especially new hypoglycemic drugs. This topic mainly focuses on the hypoglycemic risk of hypoglycemic drugs, the safety and effectiveness of hypoglycemic drugs in diabetes patients with renal insufficiency. We hope to provide more evidence and suggestions for the clinical application of these hypoglycemic drugs.
We welcome submissions of Original Research and Meta-analysis on the following subtopics, but not limited to:
• Hypoglycemic drugs and hypoglycemia
• Hypoglycemic drugs and renal function
• Effects of DPP-4i and GLP-1 RAs on blood pressure in patients with diabetes
With the development of drugs for type 2 diabetes mellitus (T2DM), many new hypoglycemic drugs have been widely used in clinic, such as dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i). These drugs have significant hypoglycemic effect, low risk of hypoglycemia, with cardio- and renal-protective effect.
For instance, the incretin effect, which is the amplification of insulin secretion when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body tolerate carbohydrate/glucose ingestion. Incretin peptides regulate islet hormone secretion, gut motility, appetite and body weight, and immune function, providing a scientific basis for utilizing incretin-based therapies in the treatment of type 2 diabetes. SGLT-2 inhibitors could also hypothetically lower albuminuria by restoring the charge and/or size selectivity of the glomerular basement membrane. Alternatively, improvement in tubular reabsorption of filtered albumin can potentially decrease albuminuria. 6 SGLT-2 inhibition reduces the reabsorption of filtered sodium and glucose in the proximal tubule, and thereby reduces the oxygen-consuming transport workload.
These novel hypoglycemic drugs bring benefits to patients with diabetes more than hypoglycemic effect. It is necessary to evaluate the safety of these new hypoglycemic drugs. Meanwhile, it is also hoped that more research should provide evidence and recommendations for effective and safe clinical use of these new hypoglycemic drugs.
This Research Topic aims to evaluate the safety of hypoglycemic drugs, especially new hypoglycemic drugs. This topic mainly focuses on the hypoglycemic risk of hypoglycemic drugs, the safety and effectiveness of hypoglycemic drugs in diabetes patients with renal insufficiency. We hope to provide more evidence and suggestions for the clinical application of these hypoglycemic drugs.
We welcome submissions of Original Research and Meta-analysis on the following subtopics, but not limited to:
• Hypoglycemic drugs and hypoglycemia
• Hypoglycemic drugs and renal function
• Effects of DPP-4i and GLP-1 RAs on blood pressure in patients with diabetes